• CML was the first malignant disease in which an acquired genetic anomaly was demonstrated as the final trigger in a chronic myeloproliferative syndrome characterized by a translocation between chromosomes 9 and 22, giving rise to the formation of the so-called Philadelphia chromosome (Ph) and the creation of a new fused gene, BCR-ABL. This gene codifies a chimeric BCR-ABL protein that presents an elevated tyrosine kinase (TK) activity, which increases the survival and proliferation of cells and inhibits apoptosis. [5] • With the advent of a new class of drugs for the treatment of CML, known as tyrosine kinase inhibitors (TKIs), the natural history of the disease has markedly changed. The current clinical practice of CML therapy is to treat patients indefinitely with a TKI and current evidence suggests that patients whose disease responds favourably to treatment with TKIs may remain essentially symptom free for at least 10 years. [2, [6] [7] • Several clinical trials have reported successful treatment-free remission (TFR) in patients with sustained deep molecular response (MR) on TKIs. [8] [9] [10] [11] [12] • Results of the phase-3 trial «Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients» (ENESTnd) have shown that a higher proportion of patients with newly diagnosed Ph+ CML-CP achieved deep MR on nilotinib vs imatinib; therefore nilotinib treatment may enable more patients to attempt TFR. [12, 13] • On the other hand, considering drug costs, it is important to underline that imatinib will lose patent protection in December 2016, with a considerable price reduction.
• The aim of this study is to assess the cost-utility of first-line nilotinib vs imatinib in patients with chronic CML eligible to start the TFR phase in the Italian healthcare setting (NHS), taking into account the loss of patent protection for imatinib.
• A previous cost-utility model in MSExcel™ and JAVA, was adapted to the Italian NHS, using a bottom-up approach, consistent with the methodology of the activity based costing. [14] [15] [16] 
MODEL STRUCTURE AND ASSUMPTIONS
• The model, an individual patient simulation model (IPS) based on a Markov framework model, simulates a cohort of 20,000 computer "patients" individually followed over time. Each "patient" has his own trajectory guided by the parameters associated with Sokal category, age, and gender and random variation, simulating real-life experience. Simulation outputs are clinical and economic outcomes averaged over all patients.
• Patients traverse through several CML health states ( Figure 1 ) and time in TFR is the key feature of the disease progression simulation.
• 1st-line discontinuation probabilities are estimated from patient-level ENEST-nd trial data.
• All of the patients remaining on 1st-line treatment at 36 months are "long-term responders":
 BCR-ABL trajectories always decreases with time.  Long-term responders who have BCR-ABL under the threshold of MR 4.5 for 2 years enter in TFR.
• Time to relapse from TFR is estimated from STIM data: Patients return to 1st-line treatment and are no longer eligible for TFR.
• After discontinuation from initial treatment, patients go to 2nd-line TKI therapy or no therapy.
• After 2 nd line, patients are removed from TKI therapy (i.e., treated with hydroxyurea) and are eligible for stemcell transplant.
MODEL ADAPTATION
• An advisory board of clinicians expert in the management of the disease, provided information on: treatment pathways, patients routine healthcare resource consumption, health care resources consumption (routine visits and instrumental tests etc.), adverse events (3/4) management and utilities.
• According to the clinicians, CML patients could start treatment with nilotinib or imatinib, at the age of 60 years while for both arms a second-line with nilotinib 800 mg is expected according to the Italian clinical practice.
• Model outcomes are expressed in Quality-Adjusted-Life-Years (QALYs) and life-years-gained (LYG).
• Costs -Euros (€) 2015 -were quantified using hospital national tariffs (in-patient and outpatient). For drugs, the maximum prices that the Italian National Healthcare Service (NHS) reimburses were considered.
• The model considers for nilotinib the cost-sharing according agreements with the National Drug Agency (AIFA) and that generic imatinib and nilotinib become available as of December 2016 and July 2023, respectively with a consequent 74% price discount for both drugs.
• The analysis, according to the clinicians, was performed with a time horizon of 15 years and costs and outcomes were discounted at 3% according to Italian Guidelines for Economic Evaluations. [17] • Incremental cost-effectiveness ratios (ICERs) were calculated to estimate the incremental cost of a TFR patient with nilotinib.
SENSITIVITY ANALYSIS
• To test the robustness of the results we considered also a scenario with no price reduction, after generic entry for nilotinib.
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• The model, according to the variables considered, estimated a very favourable [17, 18] ICERs for nilotinib vs imatinib with a value of €39,935/QALY and €31,969/LYG. 
RESULTS
BASE CASE
• Table 1 shows the unitary costs modelled in the analysis. • According to a different proportion of patients reaching MR 4.5 (Figure 2) , an incremental number of 3,773 patients are eligible to TFR with nilotinib vs imatinib (11,980 vs 8,207 ).
• Table 2 • Despite the higher monthly cost for nilotinib, an early loss of patent for imatinib and a very high discount for generic drugs (Table 1) , the average cost per patient for nilotinib is close to imatinib ( Table 2) , with a an incremental drug cost, in a time horizon of fifteen years, of +€61,692 (€201,937 vs €140,244 ), but with a total increase in healthcare costs of +€33,748 (€257,611 vs €223,863).
SENSITIVITY ANALYSIS
• Considering the scenario with no price reduction for nilotinib, the results are still favourable [17, 18] for nilotinib, with an ICER of €44,351/QALY and €35,505/LYG.
